Date: 2016-12-12
Type of information: Grant
Company: EURE-CART (EURopean Endeavour for Chimeric Antigen Receptor Therapies) project coordinated by Molmed (Italy)
Investors: European Commission’s Horizon 2020 programme
Amount: € 5.9 million
Funding type: grant
Planned used:
- The EURE-CART (EURopean Endeavour for Chimeric Antigen Receptor Therapies) project ’s main object is to conduct a multicentre, first-in-man Phase I/IIa clinical trial to demonstrate the safety and the efficacy of CD44v6 CAR T-cell immunotherapy in acute myeloid leukaemia and multiple myeloma. The project will involve a consortium of nine different partners from 6 EU countries, including clinical,
scientific and industrial groups: MolMed (Italy), Ospedale San Raffaele (Italy), Universitätsklinikum Würzburg - Klinikum Der Bayerischen JuliusMaximilians-Universität (Germany), Ospedale Pediatrico Bambino Gesù (Italy), Fundacio Privada Institut de Recerca de L'hospital de la Santa Creu i Sant Pau (Spain), Fakultni Nemocnice S Poliklinikou Ostrava
Foundation (Czech Republic), Istituto Superiore di Sanità (Italy), Acromion (Germany), ARTTIC (France).
- The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating neoplastic diseases. MolMed will manufacture both research- and clinical-grade T cells genetically modified with CD44v6- CAR vector for use in cancer immunotherapy investigated by the project.
- CD44v6 CAR T-cell immunotherapy is a Moldmed proprietary project. It has been developed by San Raffaele Hospital and Molmed has exerced its right to option right for the purchase this immune-gene therapy project against cancer in 2015.
Others:
- • On December 12, 2016, MolMed announce that the European Commission, within the Horizon 2020, has awarded a 5,903,146 Euro grant to the project called EURE-CART (EURopean Endeavour for Chimeric Antigen Receptor Therapies), of which MolMed is coordinator. The grant will partially cover R&D expenses of the project over a 48-month period. MolMed will receive € 1,994,575 out of the total amount granted and will coordinate the project.
Therapeutic area: Cancer - Oncology
Is general: Yes
